Adrenomed bags €24m in growth financing
German Adrenomed AG has bagged €24m in equity financing from HBM Healthcare Investments and Wellington Partners.
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2084 entries already.
German Adrenomed AG has bagged €24m in equity financing from HBM Healthcare Investments and Wellington Partners.
Researchers at Genentech have locally blocked lung inflammation in a mouse model for asthma by administration of an inhalable JAK1 inhibitor.
The European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd €24m for antifungal research and innovation under the InnovFin Infectious Diseases Finance Facility (IDFF).
Researchers at Cancer UK have slowed down tumour growth by simply feeding mice that carry human tumour xenografts with mannose instead of glucose.
Financial pressure on Big Pharma and biotechs increases the need for drug developers to outsource their development and manufacturing capabilities. The CDMO and CRO sector, which is further consolidating through M&A, looks well set for continued growth. As developers have to balance the need to reduce their development risk with time to market or – for biotechs – time to next financing, contract manufacturing and contract research companies clearly favour offering fully integrated services.
Researchers at IRB Barcelona report that tumours may become more aggressive following treatment with drugs that inhibit epigenetic factors.
Inflammosome inhibitor specialist Inflazome Ltd has raised €40m in a Series B financing led by Forbion with co-investors Longitude Capital, Novartis Venture Fund and Fountain Healthcare Partners.
The EU Commission’s Chief Scientific Advisors urge the Commission to revise the EU’s GMO Directive in order to harness gene editing.
Boehringer Ingelheim and Epizyme, Inc. will collaborate in the field of small molecule cancer drugs that target unaddressed epigenetic targets within the helicase and histone acetyltransferase families.
Researchers at University of Göttingen, Germany, have identified nerve excitability of motor nerve cells trigger restless legs syndrome.